背景:鼻窦肿瘤是一组罕见且异质性的鼻肿瘤。即使手术方法有了进步,鼻窦腺癌(SNAC)患者的死亡率没有显著改善,并且在某些倒置性乳头状瘤(IP)患者中发现了持续较高的复发率.5-氟尿嘧啶(5-FU)的使用已被成功描述为SNAC的辅助治疗和预防IP复发。
目的:本综述旨在提供目前使用5-FU治疗SNAC和IP的证据。
方法:进行了由三位作者组成的独立文献综述,以确定涉及使用局部5-FU治疗SNAC和IP的研究。共收集了9篇关于处置SNAC和IP的论文。
结果:关于筛窦腺癌的辅助低剂量辐射和局部5-FU联合治疗的最早研究显示,5年生存率为100%。一项评估类似方案的随访研究报告,在2年,5年和10年的调整后无病生存率为96%,87%,74%,分别。在内窥镜切除后使用辅助5-FU已经证明了类似的结果,甚至在额叶钻孔后经皮5-FU递送的新设置中也有描述。在侵袭性IP的治疗中也描述了局部5-FU。最大的病例系列描述了使用5-FU治疗18例,仅有一次复发。
结论:目前,局部5-FU的使用代表了鼻肿瘤治疗中未充分利用的治疗方式。现有文献表明,局部5-FU的新辅助使用可以改善SNAC和IP的生存率并减少复发。然而,小样本量阻碍了普通人群常规使用的提倡,有必要对5-FU进行进一步研究。
BACKGROUND: Sinonasal tumors represent a rare and heterogeneous group of rhinologic neoplasms. Even with advancements in surgical approaches, mortality rates of patients with sinonasal adenocarcinoma (SNAC) have not significantly improved and persistently high rates of recurrence in certain patients with inverted papilloma (IP) are seen. The use of 5-fluorouracil (5-FU) has been successfully described as an adjuvant treatment of SNAC and in the prevention of IP recurrence.
OBJECTIVE: This review aims to present the current evidence on the management of SNAC and IP with topical 5-FU.
METHODS: A three-author independent literature review was conducted to identify research involving the use of topical 5-FU for the treatment of SNAC and IP. A total of nine papers on the treatment of SNAC and IP were collected.
RESULTS: The earliest study looking at the combination of adjuvant low-dose radiation and topical 5-FU for adenocarcinoma of the ethmoid sinus showed a 5-year survival rate of 100%. A follow-up study evaluating a similar protocol reported adjusted disease-free survival at 2, 5, and 10 years of 96%, 87%, and 74%, respectively. Similar results have been demonstrated for adjuvant 5-FU use following endoscopic resection and have even been described in the novel setting of transcutaneous 5-FU delivery following frontal trephination. Topical 5-FU has also been described in the treatment of aggressive IP. The largest case series described the use of 5-FU for eighteen cases and demonstrated only a single recurrence.
CONCLUSIONS: The use of topical 5-FU currently represents an underutilized therapeutic modality within the treatment of rhinologic neoplasms. Available literature suggests that neoadjuvant use of topical 5-FU can improve survival and decrease recurrence for SNAC and IP. However, the small sample sizes prevent advocation for routine use in the general population and further research on 5-FU is necessary.